Skip Nav Destination
Issues
1 March 2007
-
Cover Image
Cover Image
Targeting strategies of the epidermal growth factor receptor (EGFR) with small-molecules EGFR tyrosine kinase inhibitors (TKIs) or a monoclonal antibody (cetuximab) are being developed in non-small cell lung cancer. Unlike TKIs, cetuximab potentially can provoke immunologic antitumor effects, such as antibody-dependent cellular cytotoxicity (ADCC) activity, although few studies have focused on this activity. The cover shows an immunostaining of EGFR on a cancer cell line, which express 3.51×106 EGFR molecules measured by quantitative flow cytometric analysis. Using these estimation methods, the authors demonstrated that even low EGFR expression levels on lung cancer cells, which are weakly detectable by immunostaining, are sufficient for maximum ADCC activity, and further increases in EGFR expression on the target cells have no further effect on the ADCC activity. For further details, please see Kurai et al. on page 1552 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
Molecular Pathways
Report from the FDA
Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma
Vicki L. Goodman; Edwin P. Rock; Ramzi Dagher; Roshni P. Ramchandani; Sophia Abraham; Jogarao V.S. Gobburu; Brian P. Booth; S. Leigh Verbois; David E. Morse; Cheng Yi Liang; Nallaperumal Chidambaram; Janet X. Jiang; Shenghui Tang; Kooros Mahjoob; Robert Justice; Richard Pazdur
Reviews
Human Cancer Biology
Haplotypes, Loss of Heterozygosity, and Expression Levels of Glycine N-Methyltransferase in Prostate Cancer
Yu-Chuen Huang; Cheng-Ming Lee; Marcelo Chen; Ming-Yi Chung; Yen-Hwa Chang; William Ji-Shian Huang; Donald Ming-Tak Ho; Chin-Chen Pan; Tony T. Wu; Stone Yang; Ming-Wei Lin; Jer-Tsong Hsieh; Yi-Ming Arthur Chen
Imaging, Diagnosis, Prognosis
Cancer Therapy: Clinical
Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients
Lotta Hansson; Amir Osman Abdalla; Ali Moshfegh; Aniruddha Choudhury; Hodjattallah Rabbani; Bo Nilsson; Anders Osterborg; Håkan Mellstedt
A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study
Terzah M. Horton; Debananda Pati; Sharon E. Plon; Patrick A. Thompson; Lisa R. Bomgaars; Peter C. Adamson; Ashish M. Ingle; John Wright; Adam H. Brockman; Martin Paton; Susan M. Blaney
Cancer Therapy: Preclinical
Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor
Tammie C. Yeh; Vivienne Marsh; Bryan A. Bernat; Josh Ballard; Heidi Colwell; Ron J. Evans; Janet Parry; Darin Smith; Barbara J. Brandhuber; Stefan Gross; Allison Marlow; Brian Hurley; Joe Lyssikatos; Patrice A. Lee; James D. Winkler; Kevin Koch; Eli Wallace
NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism
David Jamieson; Kerrie Wilson; Simon Pridgeon; Jane P. Margetts; Richard J. Edmondson; Hing Y. Leung; Richard Knox; Alan V. Boddy
Cancer Prevention
Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo
Vaqar Mustafa Adhami; Arshi Malik; Najia Zaman; Sami Sarfaraz; Imtiaz Ahmad Siddiqui; Deeba Nadeem Syed; Farrukh Afaq; Farrukh Sierre Pasha; Mohammad Saleem; Hasan Mukhtar
Letters to the Editor
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.